Breaking News Instant updates and real-time market news.

RHHBY

Roche

$29.71

-0.07 (-0.24%)

12:32
10/14/16
10/14
12:32
10/14/16
12:32

FDA approves Genentech's Lucentis prefilled syringe

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration approved the Lucentis, ranibizumab injection, 0.5 mg prefilled syringe, PFS, as a new method of administering the medicine. Like the Lucentis 0.5 mg vial, the 0.5 mg PFS is approved to treat people with wet age-related macular degeneration, AMD, and macular edema after retinal vein occlusion, RVO.The Lucentis PFS is the first syringe prefilled with an anti-VEGF medicine FDA-approved to treat two eye conditions. "The FDA approval of the Lucentis prefilled syringe marks a new milestone in our ongoing commitment to people affected by vision-threatening eye diseases," said Sandra Horning, M.D., chief medical officer and head of Global Product Development. "With the PFS, physicians will have a new option for administering Lucentis to the hundreds of thousands of people in the U.S. diagnosed with either wet AMD or macular edema after RVO." The Lucentis PFS allows physicians to eliminate several steps in the preparation and administration process, including disinfecting the vial, attaching a filter needle, drawing the medicine from the vial using the needle, removing the filter needle from the syringe and replacing with an injection needle. With the Lucentis PFS, physicians attach the injection needle to the syringe and adjust the dose prior to administration. The Lucentis 0.5 mg PFS is expected to be available in early 2017.

  • 19

    Oct

  • 06

    Nov

  • 10

    Nov

RHHBY Roche
$29.71

-0.07 (-0.24%)

09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.

TODAY'S FREE FLY STORIES

OXFD

Oxford Immunotec

$15.34

0.2 (1.32%)

16:45
06/22/17
06/22
16:45
06/22/17
16:45
Hot Stocks
Oxford Immunotec announces reimbursement decision for T-SPOT test in France »

Oxford Immunotec Global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVH

Evolent Health

$25.90

-0.85 (-3.18%)

16:40
06/22/17
06/22
16:40
06/22/17
16:40
Syndicate
Evolent Health files to sell 4.5M shares of Class A common stock for holders »

Goldman Sachs & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDRA

Idera Pharmaceuticals

$1.73

0.02 (1.17%)

16:34
06/22/17
06/22
16:34
06/22/17
16:34
Hot Stocks
Idera announces FDA orphan drug designation for IMO-2125 for melanoma treatment »

Idera Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:33
06/22/17
06/22
16:33
06/22/17
16:33
General news
Fed Balance Sheet Level data reported »

Week of 6/21 Fed Balance…

16:33
06/22/17
06/22
16:33
06/22/17
16:33
General news
Money Supply M2 Weekly Change data reported »

Week of 6/12 Money Supply…

MGM

MGM Resorts

$33.25

0.29 (0.88%)

16:33
06/22/17
06/22
16:33
06/22/17
16:33
Hot Stocks
Breaking Hot Stocks news story on MGM Resorts »

Soroban Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$219.77

-2.72 (-1.22%)

, BAC

Bank of America

$22.93

-0.2 (-0.86%)

16:32
06/22/17
06/22
16:32
06/22/17
16:32
Hot Stocks
All 34 banks exceed minimum requirements of Fed Stress Test »

Publicly traded banks…

GS

Goldman Sachs

$219.77

-2.72 (-1.22%)

BAC

Bank of America

$22.93

-0.2 (-0.86%)

C

Citi

$63.62

-0.21 (-0.33%)

WFC

Wells Fargo

$52.49

-0.49 (-0.92%)

JPM

JPMorgan

$87.02

-0.1 (-0.11%)

MS

Morgan Stanley

$44.61

-0.3 (-0.67%)

USB

U.S. Bancorp

$51.30

-0.7 (-1.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 14

    Jul

  • 14

    Jul

  • 18

    Jul

  • 19

    Jul

  • 25

    Jul

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 18

    Oct

  • 15

    Jan

  • 17

    Jan

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

16:30
06/22/17
06/22
16:30
06/22/17
16:30
Options
Preliminary option volume of 14.6M today »

Preliminary option volume…

GOOG

Alphabet

$957.09

-2.36 (-0.25%)

, GOOGL

Alphabet Class A

$976.62

-1.97 (-0.20%)

16:27
06/22/17
06/22
16:27
06/22/17
16:27
Hot Stocks
YouTube developing 'VR180' video format, says team working with camera makers »

Alphabet's (GOOG)…

GOOG

Alphabet

$957.09

-2.36 (-0.25%)

GOOGL

Alphabet Class A

$976.62

-1.97 (-0.20%)

LNVGY

Lenovo

$12.85

0.059 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

BBBY

Bed Bath & Beyond

$33.73

0.07 (0.21%)

16:25
06/22/17
06/22
16:25
06/22/17
16:25
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

NAT

Nordic American Tankers

$6.00

-0.02 (-0.33%)

16:25
06/22/17
06/22
16:25
06/22/17
16:25
Syndicate
Breaking Syndicate news story on Nordic American Tankers »

Nordic American Tankers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JONE

Jones Energy

16:25
06/22/17
06/22
16:25
06/22/17
16:25
Hot Stocks
Jones Energy exits Arkoma Basin with non-core asset sales »

Jones Energy announced …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

GBL

GAMCO Investors

$29.89

0.27 (0.91%)

, CIR

CIRCOR

$58.20

2.98 (5.40%)

16:24
06/22/17
06/22
16:24
06/22/17
16:24
Hot Stocks
Breaking Hot Stocks news story on GAMCO Investors, CIRCOR »

Gabelli reports 15.94%…

GBL

GAMCO Investors

$29.89

0.27 (0.91%)

CIR

CIRCOR

$58.20

2.98 (5.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:23
06/22/17
06/22
16:23
06/22/17
16:23
Hot Stocks
Bed Bath & Beyond says saw increased 'softness in transactions in stores' in Q1 »

At this time, Bed Bath…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

CPE

Callon Petroleum

$9.69

-0.06 (-0.62%)

16:21
06/22/17
06/22
16:21
06/22/17
16:21
Hot Stocks
Callon Petroleum appoints Correne S. Loeffler as Interim CFO »

Callon Petroleum has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 14

    Nov

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:21
06/22/17
06/22
16:21
06/22/17
16:21
Hot Stocks
Bed Bath & Beyond repurchased approximately $127M of common stock in Q1 »

During the fiscal 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

SGH

Smart Global

$16.20

0.45 (2.86%)

16:20
06/22/17
06/22
16:20
06/22/17
16:20
Earnings
Smart Global sees Q4 EPS 62c-66c, consensus 57c »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SNX

SYNNEX

$121.84

1.51 (1.25%)

16:19
06/22/17
06/22
16:19
06/22/17
16:19
Hot Stocks
SYNNEX approves $300M share repurchase program »

SYNNEX has approved an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

AAL

American Airlines

$48.97

0.54 (1.12%)

, HCA

HCA Holdings

$86.14

2.09 (2.49%)

16:19
06/22/17
06/22
16:19
06/22/17
16:19
General news
On The Fly: Top stock stories for Thursday »

Stocks began the session…

AAL

American Airlines

$48.97

0.54 (1.12%)

HCA

HCA Holdings

$86.14

2.09 (2.49%)

PLNT

Planet Fitness

$23.95

0.38 (1.61%)

THC

Tenet

$18.89

1.21 (6.84%)

UNH

UnitedHealth

$186.50

1.58 (0.85%)

HUM

Humana

$237.00

0.79 (0.33%)

AET

Aetna

$152.98

0.88 (0.58%)

RAD

Rite Aid

$3.08

-0.11 (-3.45%)

WBA

Walgreens Boots Alliance

$76.37

-1.75 (-2.24%)

ORCL

Oracle

$50.30

3.97 (8.57%)

SPLS

Staples

$9.20

0.54 (6.24%)

JWN

Nordstrom

$47.48

1.4 (3.04%)

WB

Weibo

$72.25

-4.71 (-6.12%)

SCS

Steelcase

$14.10

-2.2 (-13.50%)

ACN

Accenture

$122.08

-5.03 (-3.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 22

    Jun

  • 22

    Jun

  • 26

    Jun

  • 28

    Jun

  • 29

    Jun

  • 07

    Jul

  • 18

    Jul

  • 23

    Aug

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:19
06/22/17
06/22
16:19
06/22/17
16:19
Hot Stocks
Bed Bath & Beyond reports Q1 SSS from customer-facing digital channels up 20%+ »

Comparable sales in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

SNX

SYNNEX

$121.96

1.62 (1.35%)

16:18
06/22/17
06/22
16:18
06/22/17
16:18
Earnings
SYNNEX sees Q3 non-GAAP EPS $1.94-$2.02, consensus $1.92 »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:18
06/22/17
06/22
16:18
06/22/17
16:18
Earnings
Bed Bath & Beyond reports Q1 EPS 53c, consensus 66c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

SNX

SYNNEX

$121.84

1.51 (1.25%)

16:17
06/22/17
06/22
16:17
06/22/17
16:17
Earnings
SYNNEX reports Q2 non-GAAP EPS $2.08, consensus $1.79 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

$NSD

NASDAQ Market Internals

16:17
06/22/17
06/22
16:17
06/22/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:16
06/22/17
06/22
16:16
06/22/17
16:16
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.